- Home
- CMPS vs LYEL Comparison
CMPS vs LYEL Comparison
Compare CMPS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- LYEL
- Stock Information
- Founded
- CMPS 2020
- LYEL 2018
- Country
- CMPS United Kingdom
- LYEL United States
- Employees
- CMPS N/A
- LYEL N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- LYEL Health Care
- Exchange
- CMPS Nasdaq
- LYEL Nasdaq
- Market Cap
- CMPS 246.5M
- LYEL 207.7M
- IPO Year
- CMPS 2020
- LYEL 2021
- Fundamental
- Price
- CMPS $3.51
- LYEL $0.45
- Analyst Decision
- CMPS Strong Buy
- LYEL Sell
- Analyst Count
- CMPS 6
- LYEL 2
- Target Price
- CMPS $20.20
- LYEL $1.00
- AVG Volume (30 Days)
- CMPS 836.8K
- LYEL 712.8K
- Earning Date
- CMPS 05-07-2025
- LYEL 05-05-2025
- Dividend Yield
- CMPS N/A
- LYEL N/A
- EPS Growth
- CMPS N/A
- LYEL N/A
- EPS
- CMPS N/A
- LYEL N/A
- Revenue
- CMPS N/A
- LYEL $61,000.00
- Revenue This Year
- CMPS N/A
- LYEL N/A
- Revenue Next Year
- CMPS N/A
- LYEL N/A
- P/E Ratio
- CMPS N/A
- LYEL N/A
- Revenue Growth
- CMPS N/A
- LYEL N/A
- 52 Week Low
- CMPS $2.49
- LYEL $0.39
- 52 Week High
- CMPS $9.63
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- CMPS 60.07
- LYEL 42.76
- Support Level
- CMPS $2.94
- LYEL $0.43
- Resistance Level
- CMPS $3.11
- LYEL $0.48
- Average True Range (ATR)
- CMPS 0.22
- LYEL 0.05
- MACD
- CMPS 0.11
- LYEL 0.00
- Stochastic Oscillator
- CMPS 93.57
- LYEL 48.43
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.